Quantum Phar. Share Discussion Threads

[r ball] 09/7/2017 06:47

In all seriousness I would encourage attendance at AGMs. The CEO was kind enough to have a private 20 minute meeting with me afterwards. Thank you

[leontitcombe] 07/7/2017 12:07

Cheers r, sounds mainly upbeat then.

[r ball] 06/7/2017 22:03

Quite. But need exec pharma.

[rosejs2] 06/7/2017 20:08

Suggest you do not worry about the Non Execs..Plenty of experience in the Pharma Sector..

Non-executives

Ian Johnson, Non-Executive Chairman

A chartered biologist and a member of the Royal Society of Biology and the Institute of Directors, Ian was appointed Non-executive Chairman in October 2016.

Ian is an experienced Director in the healthcare and life science sector. He was founder and Chief Executive Officer of Biotrace International plc until its sale to 3M in 2006 and is currently Executive Chairman of Bioquell PLC.

Ian has also served on the boards of various public and private companies in strategic consultancy and business development capacities including Cyprotex plc, Celsis International, Evans Analytical Group, MyCelx Technologies Corporation and AOI Medical Inc.

Dr John Brown, Senior Independent Non-Executive Director

Dr John Brown was appointed Non-executive Director in October 2016.

An experienced Non-executive Director who has extensive experience in the life sciences and healthcare sectors, John is Chairman of Synpromics Ltd and the Cell and Gene Therapy Catapult and a Director of Electrical Geodesics Inc.

His board experience includes his roles as Chairman of Kyowa Kirin International, Touch Bionics Ltd, BTG plc, and AxisShield plc, and as a Director of Vectura Group plc.

[r ball] 06/7/2017 18:53

Summary:-Chris and gerrard are stabilising the company.Improved cash positionAre seeking to get uk approvals in the U.K. And Replicating abroadGot a good feeling about execs. Less so about non execs who didn't say much.Concerned over lack of pharma skills on board. Company will probably be bought in 2-3 years time.

[leontitcombe] 06/7/2017 17:04

Fair play, I need to start attending a few myself. Was it positive? Any highlights?

[r ball] 06/7/2017 16:47

I was the only one to ask questions. There has to be a point in turning up. I think they were ambit surprised.

[r ball] 06/7/2017 16:04

Yes. Asked questions. No trading update issued.

[leontitcombe] 06/7/2017 14:01

Did anyone go to the agm?

[rivaldo] 26/6/2017 14:13

Just been tipped:



"In fact, here are two stocks which appear to be cheap based on their future prospects. But does that mean they are worth buying today?

Impressive update

Reporting on Monday was service-led niche pharmaceutical developer, Quantum Pharma(LSE: QP). The company announced the disposal of Total Medication Management Services, which is a homecare dispensary and delivery business which trades as Biodose Services. The disposal is another significant step in the transition of the business as it seeks to focus on its core Specials and Niche Pharmaceuticals divisions. The initial cash consideration on disposal will be £1.75m, with a maximum additional contingent consideration of £0.2m.

The sale of the division improves Quantum Pharma's EBITDA (earnings before interest, tax, depreciation and amortisation) margin by eliminating low-margin turnover. In addition, the company's remaining divisions have traded ahead of expectations in the early months of the year. The company expects this to offset the majority of the disposed contribution from Biodose Services in the current year.

Looking ahead, Quantum Pharma is expected to report a rise in its bottom line of 31% in the next financial year. Even after today's 3%+ rise in its share price, this leaves the business trading on a price-to-earnings growth (PEG) ratio of just 0.4. This suggests its capital growth potential is high, which means it may be worth buying for the long term."

[hazl] 26/6/2017 13:13

those announcements are very reassuring......
better policies put in place to see us recovering...I feel.

[rivaldo] 26/6/2017 08:36

Agreed, very good news all round today.

N+1 Singer say this morning:

"Going forward we think the recent re-rating of the company, which is moving steadily from turnaround to growth, should continue, assuming further positive underlying momentum at the update scheduled for 9 August."

[battyliveson] 26/6/2017 08:00

Looks exactly what we wanted. Low margin revenues replaced by growing high margin core business. mgt are executing swiftly on plan. Remaining business can either grow profitably or is now a very attractive bolt on acquisition to another pharma co now that it is cleaned up. Good turnaround story.

B

[aishah] 26/6/2017 07:35

Yes, good update. Low margin business sold. Now on track for sustained recovery imo.

[ayl30] 26/6/2017 07:13

Rns looks good re disposal. Also mgt statement that they expect to be ahead of previous estimates

[a2584728] 14/6/2017 15:53

Soon by the looks of it.

[a2584728] 12/6/2017 14:56

I think there may be an update on a couple of products coming

[battyliveson] 09/6/2017 16:12

drifting down on no news as weak holders sell out. Will wait for AGM update in just under a month to gauge whether to add, hold or sell (only if nasty surprise).

B

[a2584728] 30/5/2017 12:32

Great buying opportunity.

[rosejs2] 30/5/2017 10:24

A number of possible reasons for today's drop, Market Makers wanting stock so dropping the price to hit various Stop Loss numbers, short sellers (Not a good idea with the spread between buy and sell nearly 10%) or the final off loading by an Institution who held shares below the notifiable 3% mark... With a recent positive update from the board regarding their turnaround plans and future strategy.. All to play for.

[ali47fish] 30/5/2017 09:40

well it down a hefty 6pc on no news- is this a buy opp anyone please!

[rosejs2] 22/5/2017 17:34

Or the sale of the MEDICATION ADHERENCE Division...

[a2584728] 22/5/2017 17:16

I think we may get some positive news pretty soon on new licenses